NextCure, Inc. (NXTC) vs Radiopharm Theranostics Limited - Sponsored ADR (RADX)

NextCure, Inc. and Radiopharm Theranostics Limited - Sponsored ADR are both Biotechnology companies. NextCure, Inc. and Radiopharm Theranostics Limited - Sponsored ADR are of similar size ($25.4M and $24.7M). Across the 6 metrics below, Radiopharm Theranostics Limited - Sponsored ADR leads on 4 and NextCure, Inc. on 2.

Valuation

Metric NXTC RADX Biotechnology median
P/E n/m — 7.88
P/S 0.99 — 11.47
P/B 2.22 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.49 n/m 10.73
Earnings yield (171.26%) — (28.84%)
Free cash flow yield (138.87%) 0.00% (23.03%)

Profitability

Metric NXTC RADX Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (195.22%) 0.00% (57.72%)
Return on assets (121.60%) 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NXTC RADX Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 17.75% (1.97%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric NXTC RADX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.47 1.16 4.73
Net debt to EBITDA 0.75 0.07 0.96

Dividend

Metric NXTC RADX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric NXTC RADX Biotechnology median
Market cap 25.36m 24.68m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack